کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Prevalence of Hepatitis D in the Eastern Mediterranean Region: Systematic Review and Meta Analysis

Neda Amini 1, Seyed Moayed Alavian 2,*, Ali Kabir 3,4, Seyed Hossein Aalaei-Andabili 2, Seyed Yasser Saiedi Hosseini 2, Mario Rizzetto 5

1 Tehran University of Medical Sciences, Students’ Scientific Research Centre, Tehran, IR Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Center for Educational Research in Medical Sciences, Tehran University of Medical Sciences, Tehran, IR Iran
5 Division of Gastroenterology, Molinette – University of Turin, Corso Bramante, Turin, Italy

* Corresponding author: Seyed Moayed Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel.: +98-2188067114, Fax: +98-2188067114, E-mail: editor@hepatmon.com.

ABSTRACT

Background: Hepatitis D Virus (HDV) causes the most threatening form of chronic viral hepatitis. To date, there is no overall estimation of HDV prevalence in the Eastern Mediterranean Region Office of WHO (EMRO) countries.

Objectives: To provide a clear estimation of HDV prevalence in the aforementioned region.

Patients and Methods: In the current systematic review, databases such as PubMed, Embase, Web of sciences and Google scholar were searched Until December 2010. The summary estimate of HDV prevalence in the EMRO region was calculated as an average of the pooled infection prevalence of each country weighted by the ratio of the country’s HBV population to the study’s sample size in the survey data analysis.

Results: We included 62 eligible studies. The weighted mean of HDV prevalence in the EMRO region was 14.74% (95% CI: 14.73 – 14.77), 27.8% (95% CI: 27.78 – 27.82), 36.57% (95% CI: 36.55 – 36.59) and 16.44% (95% CI: 16.42 – 16.46) in asymptomatic HBsAg positive carriers, chronic hepatitis patients, cirrhosis/ hepatocellular carcinoma, and high risk group, respectively. Among the asymptomatic HBsAg positive group, HDV prevalence was increased by years in older patients in Saudi Arabia but its prevalence was decreased in Iran. No specific pattern was seen according to chronological analysis during years among the EMRO countries.

Conclusions: HDV infection is endemic in the EMRO countries and it is more common among patients with severe forms of hepatitis. Due to the high HDV infection rates in the EMRO countries, we recommend blood screening for HDV infection in this region.

Keywords: Epidemiology; EMRO; Hepatitis D; Meta-Analysis; Prevalence
1. Background

The hepatitis D virus (HDV) was detected by Rizzetto among patients with a severe form of HBV infection in the year of 1977 (1). HDV is a deformed and incomplete delta agent RNA virus which is dependent on HBsAg for transmission and replication (2). HDV leads to fulminant hepatitis and further disease progression among hepatitis B infected patients. The long term co-infection of HBV and HDV is associated with a higher risk of cirrhosis and hepatocellular carcinoma. Around 15% of only HBV infected patients progress to cirrhosis versus up to 80% of HBV and HDV co-infected patients who develop cirrhosis (3). It has been estimated that almost 5% of HBV infected patients have HDV co-infection (4). The epidemiologic distribution of HDV infection differs throughout the world and in countries such as Iran (5) and in the USA varies from region to region (6). Evidences show that HDV is highly endemic in the Middle East area (7).

2. Objectives

Since there are few epidemiological studies in the Eastern Mediterranean Region Office of WHO (EMRO) countries and there is no any overall estimation of hepatitis D infection prevalence in this region, we designed a literature review. In order to provide a clear and comprehensive presentation of available data, we decided on a systematic review on epidemiological characteristics and on finding gap knowledge about HDV infection among HBV infected patients of the EMRO countries according to quantitative analysis of available epidemiological data from this region.

3. Patients and Methods

3.1. Search Strategy

We made an electronic literature search through Scopus, Web of sciences, Google scholar, Embase and two MEDLINE database engines; Pubmed and Ovid using different combinations of following key words “hepatitis D, Delta antigen, HDV, hepatitis delta virus” and the name of the EMRO countries as; Afghanistan, Bahrain, Cyprus, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, United Arab Emirates, and Yemen. The Iranian databases such as MagIran, IranMedex and SID were also searched with relevant English and Persian key words. We searched published/unpublished information until December 2010. Search sensitivity was checked by considering duplicated papers. If the full text of articles were not accessible, e-mails were sent to authors. After one month, if authors did not give a response, informative abstracts were used for data extraction. The articles with no informative abstracts were omitted.

3.2. Study Selection

Published studies in English, Persian, and French were eligible if they met the following criteria:

1) Appropriate study design: cross-sectional, case-control, and case-series or cohort,
2) Studies with clearly stated information about the number of HBsAg positive patients infected with HDV in the EMRO countries. The following represents our exclusion criteria:
   1) Studies with all patients having acute hepatitis B because the pattern of HDV is different in chronic and acute hepatitis.
   2) Articles were about the genotypes.
   3) All participants were under 15 years old.
   4) Papers included HIV positive patients as participants.
   The names of the authors or journals had no impact on the decision to exclude or include the articles.

3.3. Quality Assessment

A critical appraisal (CA) was done using Epible check list form (8) to evaluate the adequacy of the sample size, design, data collection, and the resultant presentation. Each paper was appraised by two authors individually. Then, the two CA scores of each paper were compared together. If the difference was more than 10 percent, authors negotiated to reach the same CA score. Based on the total CA score, articles were divided into low (< 40%), moderate (40% - 70%), and high (> 70%) quality. Low quality papers were not included in the main analysis except in subgroups analysis according to the papers’ quality.

3.4. Data Extraction

Information was entered into Microsoft Office Excel 2007. The name of country, the author’s name, the year of study, the sample size, HBsAg positive frequency, the mean age, and the total prevalence of HDV were extracted. HDV prevalence was calculated in different subgroups consisting of: 1) cirrhotic and hepatocellular carcinoma 2) asymptomatic HBsAg positive carriers consisting of inactive carriers, general population, blood donors and healthy pregnant women 3) chronic hepatitis patients and 4) high risk group including intravenous drug abusers (IDU) and hemodialysis patients. Moreover, standard errors (SE) were calculated using the following formula: $SE = \sqrt{(P(1-P)/N)}$ (P = prevalence, N= sample size)

3.5. Statistical Analysis

The aggregated prevalence of each country was computed by “metan” command in which is an average of the individual study results weighted by the inverse of their variances using a fix/random model (DerSimonian and Laird) based on the heterogeneity test result that was showed by Q squared, I - squared and Tau - squared statistics. For Q statistics, due to the low power of this
test, a minimum cut-off P value of 0.1 was established as a threshold of heterogeneity. I-squared lies between 0% and 100% and Tau-squared showed the variance between studies. The summary estimate of HDV prevalence in the EMRO region was calculated as an average of the pooled infection prevalence of each country weighted by the ratio of the country’s HBV population to the study’s sample size in the survey data analysis. Subgroup analysis was planned depending on the disease pattern (cirrhotic and hepatocellular carcinoma, asymptomatic HBsAg positive carriers, chronic hepatitis patients, and the high risk group) and quality assessment scores (low, moderate, and good). The analysis was performed with Stata 11 software (Stata Corp. LP).

4. Results

4.1. Search Results

Two hundred and four articles were found in the literature review, 145 of them were potentially related to HDV in the EMRO countries. After reviewing of the abstracts and titles, 38 articles (9-43) were omitted since they were related to the genotypes or were editorial, and review articles. In addition, three studies (42-44) with duplicated data of the same populations were excluded. In addition, sixteen citations were omitted (43-57) as they were not available online, and their abstracts did not provide sufficient information. Although we contacted their authors or publishers, their full texts were not made accessible. Eighteen studies (56-73) with all patients having acute hepatitis B were excluded and three other (74-76) studies were also omitted because all participants were children. Ten (77-86) further studies were omitted because they were categorized in a low quality group. Thus, the 62 (5, 87-143) studies to be included were identified assessing the HDV prevalence in the EMRO countries and fulfilling inclusion criteria. Out of these, 19 studies (95-113) were in Iran, nine studies (129-137) in Saudi Arabia, seven studies (5, 119-124) in Pakistan, six studies (89-94) in Egypt, four studies (138-141) in Tunisia and Somalia (125-128) and two studies (142, 143) in Yemen. There was one study of other countries which consisted of: Afghanistan (87), Djibouti (88), Jordan (114), Kuwait (115), Lebanon (116), Morocco (117), and Oman (118). There were no data available from the following countries: Bahrain, Cyprus, Iraq, Libya, Palestine, Qatar, Syria, and United Arab Emirates. Three studies (127-129) had case-control design and the other 59 were cross-sectional.

4.2. HDV Infection Prevalence Among Asymptomatic HBsAg Positive Carriers

Information about HDV prevalence of asymptomatic HBsAg positive carriers was available from 12 countries (Table 1). The pooled HDV prevalence among this group in the countries with more than one study was 24.6% (95% CI: 23.66 – 29.15) in Sudan, 18.33% (95% CI: -2.00 – 38.65) in Pakistan (Figure 1), 15.97% (95% CI: 9.40 – 22.55) in Tunisia, 10.7% (95% CI: 0.73 – 20.87) in Egypt (Figure 2), 7.2% (95% CI: 3.73 - 10.32) in Saudi Arabia (Figure 3), 4.94% (95% CI: 3.73 - 6.15) in Iran, and 1.56% (95% CI: 1.10 – 2.03) in Yemen. Infection prevalence in the countries for which only one report was available ranged from 1%, 1.67% and 2% in Lebanon, Djibouti, and Jordan to 16.8% and 28.6% in Somalia and Afghanistan. The pooled or individual estimation of HDV prevalence in these countries provided in (Figure 4).

According to the survey data analysis method, the HDV prevalence for each country was weighted using the ratio of the country’s HBV population to the study’s sample size. Using this method, the weighted mean HDV prevalence in the EMRO countries was 14.74% (95% CI: 14.73 – 14.77) among asymptomatic HBsAg positive group.

### Table 1. Characteristics of Studies in Asymptomatic HBsAg Positive Carriers in EMRO Countries

| Name of Country | First Author/Publication, y | Quality Assessment Score | Sample Size | HDV Prevalence, % |
|-----------------|-----------------------------|--------------------------|-------------|-------------------|
| Afghanistan     | Jacobson, Ira M./1985        | moderate                 | 7           | 28.60%            |
| Djibouti        | E. A. Abbatte/1989           | moderate                 | 656         | 1.67%             |
| El Zayadi, A./1988 | moderate                | 48                   | 8.30%       |
| Darwish, M. A./1992 | moderate               | 41                   | 21.90%      |
| Zaki, S./2010    | moderate                    | 6                      | 0           |
| Iran            | Malekzadeh, R./1989          | moderate                 | 158         | 13.90%            |
| Rezvan, H./1990  | moderate                    | 120                     | 2.50%       |
| Amin, S./1993    | good                        | 123                     | 2.40%       |
| Habibi, F./2000  | moderate                    | 200                     | 9.00%       |
| Karimi, A./2000  | moderate                    | 154                     | 1.30%       |
| Hassanjani Roshan, M. R./2004 | moderate       | 546                     | 2.00%       |
| Alavian, S.M./2004 | moderate               | 102                     | 2.00%       |
| Roshandel, G./2007 | good                    | 139                     | 5.80%       |
| Country     | Author(s) | Year | Subtest | Prevalence % |
|-------------|-----------|------|---------|--------------|
| Jordan      | Toukan, A.U. | 1987 | moderate | 2.00%        |
| Lebanon     | Ramia, S. | 2007 | moderate | 0.90%        |
| Pakistan    | Saeed Ur, R. | 2000 | moderate | 10.00%       |
|             | Baig, S. | 2009 | moderate | 7.98%        |
|             | Seetlani, N.K. | 2009 | moderate | 37.00%       |
| Somalia     | Aceti, A. | 1989 | moderate | 22.00%       |
| Saudi Arabia| Ashraf, S. J. | 1986 | moderate | 6.60%        |
|             | Ramia, S. | 1988 | moderate | 7.95%        |
|             | Sheth, K. V. | 1989 | moderate | 11.20%       |
|             | El Nasser, M. N. | 1992 | moderate | 11.40%       |
|             | Fathalla, S. E. | 1994 | moderate | 2.75%        |
|             | Al Taif, I. | 2004 | moderate | 3.30%        |
| Sudan       | Al-Arabi, M.A. | 1987 | moderate | 25.00%       |
|             | Hyams, K.C. | 1989 | good     | 27.80%       |
| Tunisia     | Jenhani, F. | 1990 | moderate | 33.00%       |
|             | Triki, H. | 1997 | moderate | 16.10%       |
|             | Skouri, H. | 2004 | moderate | 8.00%        |
|             | Djebbi, A. | 2009 | moderate | 6.80%        |
| Yemen       | El Guneid, A. M. | 1993 | moderate | 1.33%        |
|             | Scott, D. A. | 1990 | moderate | 1.80%        |

Figure 1. Forest Plot of HDV Infection Prevalence among Different Subgroups in Pakistan

Figure 2. Forest Plot of HDV Infection Prevalence among Different Subgroups in Egypt
Prevalence of Hepatitis D in EMRO

Amini N et al.

Figure 3. Forest Plot of HDV Infection Prevalence among Different Subgroups in Saudi Arabia

Figure 4. Regional Distribution of Pooled or Individual Prevalence of Hepatitis D Virus Infection among Asymptomatic HBsAg Positive in EMRO Countries

Table 2. Characteristics of Studies among Patients with Chronic Hepatitis Disease in EMRO Countries

| Name of Country | First Author/Publication, y | Quality Assessment Score | Sample Size | HDV Prevalence, % |
|-----------------|-----------------------------|--------------------------|-------------|-------------------|
| Egypt           | El Zayadi, A./1988          | moderate                 | 24          | 58.30%            |
|                 | Darwish, M. A./1992         | moderate                 | 51          | 21.00%            |
|                 | Darwish, M. A./1992         | good                     | 51          | 23.50%            |
|                 | Angelico M/1997             | moderate                 | 21          | 19.04%            |
|                 | Youssef A./2009             | moderate                 | 10          | 0%                |
| Iran            | Rezvan, H./1990             | moderate                 | 5           | 0%                |
|                 | Alavian, S.M./2004          | moderate                 | 155         | 7.70%             |
|                 | Taghavi, S. A./2008         | good                     | 93          | 9.70%             |
|                 | Somi, M. H./2009            | moderate                 | 547         | 12.70%            |
|                 | Hajiani, E./2009            | good                     | 88          | 45.50%            |
|                 | Alizadeh, A. H./2010        | moderate                 | 30          | 13.30%            |
|                 | Zahedi, M./2010             | good                     | 196         | 10.70%            |
| Jordan          | Toukan, A. U./1987          | good                     | 42          | 21.42%            |
| Kuwait          | Alkandari, S./1988          | moderate                 | 48          | 31.00%            |
| Lebanon         | Ramia, S./2007              | moderate                 | 92          | 2.17%             |
| Morocco         | Rioche, M./1987             | moderate                 | 85          | 1.00%             |
| Pakistan        | Saeed Ur, Rahman/2000       | moderate                 | 22          | 36.80%            |
|                 | Mumtaz, K./2005             | good                     | 8721        | 16.60%            |
|                 | Das, K./2008                | moderate                 | 73          | 31.50%            |
|                 | Seetlani, N.K./2009         | moderate                 | 141         | 67.00%            |
|                 | Baig, S./2009               | moderate                 | 70          | 35.00%            |
| Somalia         | Aceti, A./1991              | moderate                 | 41          | 56.30%            |
|                 | Bile, K./1993               | moderate                 | 44          | 38.60%            |
| Saudi Arabia    | Fathalla, S. E./1994        | moderate                 | 52          | 7.69%             |
|                 | Al Traif, I./2004           | moderate                 | 780         | 8.60%             |
| Tunisia         | Djebbi, A./2009             | moderate                 | 39          | 38.40%            |
| Yemen           | el Guneid, A. M./1993       | moderate                 | 25          | 4.00%             |
4.3. HDV Infection Prevalence Among Patients With Chronic Hepatitis

Articles of 12 countries revealed information on the HDV infection rate among patients with chronic hepatitis (Table 2). The pooled HDV prevalence was 47.36% (95% CI: 30.24 - 64.49) in Somalia, 37.38% (95% CI: 14.76 - 60) in Pakistan (Figure 1), 24.37% (95% CI: 6.62 - 42.41) in Egypt (Figure 2), 14.4% (95% CI: 7.72 - 21.07) in Iran, and 8.15% (95% CI: 7.25 - 9.04) in Saudi Arabia (Figure 3). The pooled or individual estimation of HDV prevalence among chronic hepatitis patients demonstrated in Figure 5. The weighted mean HDV prevalence was 27.8% (95% CI: 27.78 - 27.82) in the EMRO countries.
4.4. HDV Infection Prevalence Among Cirrhotic/HCC Patients and High Risk Group

Table 3 showed information about HDV prevalence among both cirrhotic/HCC patients and high risk groups. The pooled HDV prevalence among cirrhotic/HCC patients was 53.77% (95% CI: 22.71 - 82.84) in Pakistan (Figure 1), 33.20% (95% CI: 21.64 – 44.76) in Somalia, 30.47% (95% CI: 9.76 - 51.19) in Iran and 29.6% (95% CI: -0.39 - 59.59) in Egypt (Figure 2). The weighted mean HDV prevalence of patients with cirrhosis or hepatocellular carcinoma was 36.57% (95% CI: 36.55 – 36.59) among nine countries revealing information on the HDV infection rate in cirrhotic/HCC patients. In the high risk group consisting of IDU and hemodialysis patients, the weighted mean HDV prevalence in six countries was 16.44%. (95% CI: 16.42 - 16.46).

4.5. HDV Prevalence According to Quality Assessment Score

According to the quality assessment score, ten articles were categorized in the good quality group (5, 29, 91, 97, 99, 102, 109, 111, 113, 114). In this group, HDV prevalence was 16.25%, 16.60%, 44.32% among asymptomatic HBsAg positive carriers, chronic hepatitis patients and cirrhotic/HCC patients, respectively. HDV prevalence in moderate quality group consisted of 52 articles (87-90, 92-96, 98, 100, 101, 103-108, 110, 112, 115-145) among asymptomatic HBsAg positive carrier was 14.02% and among chronic hepatitis patients was 28.73%. In cirrhotic/HCC and high risk group, HDV prevalence was 36% and 16.44%. In low quality group, we had ten articles (77-86). The HDV prevalence was 44.50%, 22.67%, and 59.44% among asymptomatic HBsAg positive carriers, chronic hepatitis, and cirrhotic/HCC patients, respectively. We had no data among the high risk group in low quality and good quality articles.

4.6. Chronologic Changes of HDV Prevalence

To detect the HDV prevalence pattern over the years in the EMRO countries, we sorted HDV infection prevalence by year for each country. This analysis also was repeated for the whole EMRO region. The data was not shown; however, no specific pattern was seen. The overall estimation for three age categories (< 20, 20-30, > 30) was calculated in different populations (asymptomatic HBsAg positive persons, chronic hepatitis, cirrhotic and hepatocellular carcinoma). Due to lack of information for most countries, this table was not shown in the results. The only recognizable patterns was the increase of HDV prevalence in Saudi Arabia by year among the asymptomatic HBsAg positive group and decrease of infection prevalence by year in Iran of the same group.

Table 4. Correlation Among HBeAg, ALT, and HBV-DNA

| Author (Citation) | Country | Prevalence, % | Sample Size, Target Population | Neighbors City in EMRO Region, Prevalence |
|------------------|---------|---------------|---------------------------------|------------------------------------------|
| **African Region** |         |               |                                 |                                          |
| Nwokediuko S (154) | Nigeria | 15.60% | Asymptomatic HBsAg positive | Libya (no data) |
| Rapicetta M (155) | Ethiopia | 5.80% | Asymptomatic HBsAg positive | Sudan (26.40%) |
| Foupouapouognigni Y (156) | Cameroon | 17.60% | Asymptomatic HBsAg positive | None |
| **Americas Region** |         |               |                                 |                                          |
| Fonseca JC (147) | Brazil | 34.40% | Asymptomatic HBsAg positive | None |
| Hadler S. C (148) | Venezuela | 34.00% | Asymptomatic HBsAg positive | None |
| **South-East Asia Region** |         |               |                                 |                                          |
| Kim H. S (157) | Korea | 0.32% | Chronic hepatitis | None |
| Chakraborty P (158) | India | 8.10% | Chronic hepatitis | Pakistan (37.38%) |
| **European Region** |         |               |                                 |                                          |
| Degertekin H (149) | Turkey/middle east | 27.10% | Meta analysis | Iran (4.94%) |
| Gaeta GB (6) | Italy/Europe | 8.30% | Chronic hepatitis | None |
| **Western Pacific Region** |         |               |                                 |                                          |
| Chen X (159) | China | 3.16% | Asymptomatic HBsAg positive | Afghanistan (28.60%) |
| Tsatsralt-Od B (150) | Mongolia | 43.00% | Chronic hepatitis | None |
5. Discussion

The result of this study revealed HDV prevalence was 15% and 26% among asymptomatic HBsAg positive carriers and chronic hepatitis patients, respectively. This result indicates HDV infection is endemic in the EMRO region. In addition, the most prevalence of HDV infection was in African countries of EMRO regions such as Egypt, Sudan, Tunisia and Somalia. As a result, North Africa must be considered as a high HDV prevalence area in addition to central Africa, southern America, and Mediterranean countries since they were mentioned in the previous studies (146). The comparison of HDV prevalence between different WHO regions was demonstrated in Table 4. In the African region, the infection prevalence is near to mean of the HDV prevalence in the EMRO region. In other regions, some countries such as Brazil (147), Venezuela (148), Turkey (149), and Mongolia (150) have higher HDV infection prevalence in comparison with the EMRO countries. Our analysis showed that a cirrhotic/HCC group had the most HDV infection prevalence when correlated with a previous study which has consistently shown most patients with HBV and HDV co-infection have a more severe progression to cirrhosis and HCC (151, 152). Furthermore, HDV infection prevalence was calculated to be 16% among IDU and hemodialysis group (high risk group) that is less common in comparison with asymptomatic and chronic hepatitis patients. This result is in contrast with previous studies (146, 153) and indicates that IDU and people exposed to blood and its products were at a high risk of acquiring HDV infection. This result may be due to our limited existing data among IDU and hemodialysis group. The analysis according to the quality assessment score showed that HDV prevalence was overestimated among asymptomatic HBsAg positive carriers in low quality articles. Also, this prevalence was underestimated among chronic hepatitis patients. Furthermore, the subject of HDV infection prevalence in good quality articles was closed to overall estimation. We had some limitations in our review such as lack of good coverage caused by hand searching the library and dissertations. Also, for most of the countries, our literature review was limited to English. As a result, the information in native languages was not operational. Another limitation was related to HDV detection method which was ELISA for most articles. Hence, the confirmation of ongoing HDV infection by PCR testing of HDV RNA was missing. The impact of this lack of information is that patients with and without active delta infection cannot be differentiated. One of our goals in this systematic review was the calculation of a pooled estimation for possible risk factors to identify the most important routes of HDV transmission in the EMRO region. However, the numbers of articles that revealed information in this field were rare. Therefore, we could not perform that analysis. Many articles were done before the year 2000 and some countries had one or two HDV prevalence estimations in close time points. Due to lack of information, a recognizable pattern of HDV prevalence was not detectable during recent years. In addition, most studies were performed on young adults (30-50) therefore; we could not access the impact of age on HDV acquisition in the EMRO region. One of the strengths of this study was doing the survey data analysis in addition to usual ‘Meta’ command that helps increase generalizability of results to the whole population. Twenty two countries (total population is 798,782,000) are in the EMRO region and the data from 92% (738,901,000) of this population was used in our analysis. In conclusion, the HDV infection is endemic in the EMRO countries; and this prevalence is very high in African part of the EMRO region. Furthermore, it is more common among patients who have a severe form of hepatitis. Due to these results, we would recommend blood screening for HDV infection. Furthermore, new surveys are needed to detect infection prevalence in different points of time and to provide the updated data about HDV prevalence in the EMRO region countries.

Acknowledgements

None declared.

Authors’ Contribution

Amini N made an electronic literature search. A critical appraisal (CA) was done by Saiedi Hosseini SY, Aalaei-Andabili SH and Amini N. Kabir A and Amini N analysed the data. All the authors contributed in interpretation of results. Alaviain SM and Rizzetto M read the article and supervised the team.

Financial Disclosure

None declared.

Funding/Sponsor

None declared.

References

1. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut.1977;18(12):997-1003.
2. Hajiani E, Hashemi S, Jalali F. Seroprevalence of Delta Hepatitis in Patients with Chronic Hepatitis B and its Clinical Impact in Khuzestan Province, Southwest Iran. Hepat Mon.2009;9(4):287-92.
3. Yamaguchi Y, Delehouzee S, Handa H. HIV and hepatitis delta virus: evolution takes different paths to relieve blocks in transcriptional elongation. Microbes Infect.2002;4(11):659-75.
4. Taghavi SA, Sedighi S, Mehrabani D, Khademolhosseini F. Hepatitis D in Chronic Active Hepatitis B: Prevalence, Liver Enzyme Levels and Histopathology- an Epidemiological Study in Shiraz, Southern Iran, 2003-2004. Hepat Mon.2008;8(4):248-51.
5. Mumtaz K, Hamid SS, Adil S, Alaq A, Islam M, Abid S, et al. Epidemiology and clinical pattern of hepatitis delta virus infection in
Prevalence of Hepatitis D in EMRO

Amini N et al.

Pakistan. J Gastroenterol Hepatol.2005;20(10):535-7.
6. Gaeta GB, Stroffolini T, Chiaramonte M, Asicone T, Sornaiuolo G, Lobello S, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology.2000;32(4 Pt 1):824-7.
7. Huse F, Limbarto A, Nemecek V, Hasoua L. Hepatitis D. Acta Virol.2005;49(4):219-25.
8. Glynn L. EBIL Critical Appraisal Checklist. Memorial University of Newfoundland; Available from: http://www.munhsn.de/pdf/EBIL20-Critical20Appraisals20Checklist.pdf.
9. Abbas Z, Jafari W, Raza S. Hepatitis D: Scenario in the Asia-Pacific region. World J Gastroenterol.2010;16(15):554-62.
10. Alavian SM. We Have More Data Regarding Epidemiology of Hepatitis D in Iran but There are Defects to be Filled Yet. Hepat Mon.2008;8(4):245-7.
11. Alavian SM. Hepatitis D in hemodialysis setting: A short Review. Acta Med Sal.2009;7(1):1-10.
12. Alavian SM. Hepatitis D in hemodialysis setting: A short Review. Acta Med Sal.2009;7(1):1-10.
13. Alavian SM. Untought of Problems Regarding Hepatitis D Virus Infection. Hepat Mon.2010;10(2):79-9.
14. Alavian SM, Alavian SH. Hepatitis D virus Infection; Iran, Middle East and Central Asia. Hepat Mon.2005;5(4):137-43.
15. Aly MA, Mangood AM, Essa MH, Refaat MA, Helmy E, Makarem SS. The pattern of bilharzial infection with hepatitis B virus associated with delta agent. J Egypt Soc Parasitol.1989;19(2 Suppl):699-708.
16. Behzadian F, Sabahi F, Karami M, Behzadifalavian SM, Zand Y. Detection and genotyping of hepatitis D virus from HBsAg positive patients in Iran using RT-PCR. Iran J Biotech.2006;4(3):174-9.
17. Toukan AU, al-Kandari S. The role of hepatitis D virus in liver disease in the Middle East. Prog Clin Biol Res.1991;364:53-8.
18. Wallace MR, Hale BR, Utz GC, Olson PE, Earhart KC, Thornton SA, et al. Endemic Infectious Diseases of Afghanistan. Clin Infect Dis.2002;34(5 Suppl 5):S70-S207.
19. Zaki Mel S, Salama OS, Mansour FA, Hosseini S. Hepatitis E virus coinfection with hepatotropic viruses in Egyptian children. J Virol Immunol.2008;41(3):254-6.
20. Zhang YY, Tseia E, Hanson BG. Phylogenetic analysis of hepatitis D viruses indicating a new genotype I subgroup among African isolates. J Clin Microbiol.1996;34(12):3023-30.
21. Zeiber BF, Quaraishy MS, Afsar S, Akhtar N, Kumar A, Dodani SK. Treatment outcome in patients of hepatitis B with hepatitis D: experience of 4 years at a tertiary care centre in Pakistan. J Coll Physicians Surg Pak.2007;17(3):202-3.
22. Ghoolamezra Z, Shahryar S, Abbasali K, Hamidreza J, Abdolvahab M, Khodadabadi K, et al. Seroprevalence of hepatitis B virus and its coinfection with hepatitis D virus and hepatitis C virus in Iranian adult population. Int J Infect Dis.2007;11(5):263-8.
23. Rezvan H, Forouzandeh B, Taroyan S, Fadaei S, Azordegan F. Epidemiology of Delta virus infection and its clinical impact in Iran. J Iran Med Council.1993;13(10):171-8.
24. Rosedahl G, Semnani S, Abdolah N, Besharat S, Keshkara AA, Joshasaii H, et al. Prevalence of Hepatitis D virus infection in hepatitis B surface antigen-positive subjects in Golestan province, northeast Iran. Iran Microbiol Immunol Infect.2008;41(3):227-30.
25. Ali Hym, Yassen SA. Prevalence of hepatitis B and D viral infections among hospital personnel in Mosul-Iraq. Qatar Med J.2000;10(2):32-3.
26. Arya SC, Ashraf SJ, Pathak VP, Nanda V, Parande CM, Tajuddin S. Serological profiles for HBV, HDV, HIV-1 and HTLV-1 in Saudi patients with a malignancy. J Commun Dis.1999;31(2):216-9.
27. Ashraf SJ, Arya SC, Arendrup M, Krohggaard K, Parande CM, Orskov B, et al. Frequencies of hepatitis B, delta and HTLV-III virus markers in Saudi Arabia. Liver 1996;16(2):273-7.
28. Eleftheriou A, Teloni F, Ioannou P. HDV infection in Cyprus. Prog Clin Biol Res.1993;382:277-85.
29. el-Hawey AM, Abdel-Rahman MM, Ibrahim MS, Abdel-Rahman AH, Salama MM. Delta virus versus HBsAg in chronic active hepatitis B carriers in Giza, Egypt. J Egypt Soc Parasitol.1991;21(2):351-5.
Prevalence of Hepatitis D in EMRO

Amini N et al.

54. Malik IA, Ahmed A, Iqbal M, Legters LJ, Luqman M, Akhtar MA. Infection with delta agent in Pakistan. Introduction of a new hepatitis agent. J Pak Med Assoc. 1988;38(5):126-8.

55. Massoud M, Helmy O, Saleh WA. Hepatitis D anti-bodies in some HBs Ag positive in Saudis at Riyadh. J Egypt Soc Parasitol. 1999;29(2):560-5.

56. Safer I, Ben Chaabene N, Melki W, Saffar H. Epidemiology of viral hepatitis in Tunisia. Rev Epidemiol Sante Publique. 2006;54(4):377-80.

57. Shobokshi OA, Serebour FE. Prevalence of delta antigen/antibody in various HBsAg positive patients in Saudi Arabia. Clin Biol Res. 1987;234(4):471-5.

58. Torabi S, Ebrahimpoor S, Maljaei S, Naghili B. Seroepidemiological studies of Hepatitis Delta (HDV) in HBsAg positive individuals in Tehran. J Urmia Univ Med Sci. 2003;4(3):290-7.

59. Triki H. Epidemiology of hepatitis B virus, hepatitis C virus and Delta virus in the general population and in liver cirrhosis in Tunisia. Arch Inst Pasteur Tunis. 1994;2(1-2):1403-6.

60. Zahedi M. Serologic prevalence of hepatitis D in HBsAg positive patients in Kerman, south of Iran, 2002-2003. Kurnum Univ Med Sci 2003; p.

61. Abdel-Wahab KS, Abu-Shady EA. Evidence of a 1985-1987 outbreak of acute and chronic hepatitis in Egypt caused by a mutant hepatitis-B virus detected by spot-DNA hybridization test. J Egypt Soc Parasitol. 1992;22(2):281-93.

62. Zuberi SJ. The delta agent and hepatitis D. J Pak Med Assoc. 1988;38(1):283.

63. Al-Kandari S, Nordenfelt E, Al-Nakib B, Radakrishnan S, Al-Nakib W. Acute non-A, non-B hepatitis in Kuwait. Scand J Infect Dis. 1987;9(6):561-6.

64. Al-Kandari S, Nordenfelt E, Al-Nakib B, Hанссон BG, Ljunggren K. Delta virus and hepatitis delta virus infection in acute hepatitis in Kuwait. Scand J Infect Dis. 1988;20(1):355-9.

65. Ayed K, Gorgi Y, Pichoud C, Trepo C. Prevalence of HD Ag and anti HD by radioimmunoassay in acute and chronic HBV infections in Tunisia. Prog Clin Biol Res. 1987;234(1):1411-2.

66. Bassily S, Hyams KE, Al Ghorab NM, Ansari AA, Fanous AS. Acute sporadic hepatitis in adults living in Cairo, Egypt. Am J Trop Med Hyg. 1986;35(3):3040-4.

67. Ghahram TM, Strickland GT, Tsarvaj F, Yearbough P, Parci P, Engle R, et al. Acute viral hepatitis in Saudi Arabia: Seroepidemiological analysis, risk factors, clinical manifestations, and evidence for a sixth hepatitis agent. Clin Infect Dis. 1995;21(1):621-7.

68. Glynn MJ, Rashid A, Antro AO. Imported epidemic non-A, non-B hepatitis in Qatar. J Med Virol. 1987;21(4):375-7.

69. Gunaad AA, Naisher TM, el-Guneid AM, Hill M, Dayton R, Pal A, et al. Acute sporadic hepatitis in the Republic of Yemen. J Med Virol. 1997;51(1):149-164.

70. Haider Z, Khan AA, Rehab M, Janjua MI, Iqbal J, Chisti MA, et al. Sero-diagnosis for viral hepatitis in 93 patients admitted with acute hepatitis in three different teaching hospitals in Lahore. J Pak Med Assoc. 1994;44(4):332-4.

71. Marcus S, Al-Moslih M, Al-Tawil NG, Kassir ZA. Virological and immunological studies in patients with acute viral hepatitis. Scand J Immunol. 1993;37(2):265-70.

72. Meky FA, Stozszek SK, Abdel-Hamid M, Selim S, Abdel-Wahab MA, Mikhail N, et al. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin Infect Dis. 2006;42(5):528-33.

73. Rassam SW, Goudeau AM, Dubois F, Al-Khoury WN, Muhaye Al-Deen JA, Sadik AM. Acute viral hepatitis: An aetiological study of 253 patients. J Gastroenterol Hepatol. 1988;4(2):153-7.

74. Abdel-Fattah S, el-Kholy MS, Abdel-Fattah SM, el-Shimi S, el-Rasad MM, Mikhail TH, et al. Delta virus and hepatitis B surface antigen in chronic liver diseases. J Egypt Public Health Assoc. 1991;66(3-4):427-39.

75. Bahahkim H, Ramia S, Kurbiaan K. Combined immunoprophylaxis in the prevention of perinatal transmission of hepatitis B and hepatitis D virus infections in Saudi children. Ann Triptuediat. 1999;10(1-2):339-43.

76. Morcos MM, Mikhail TH, Hanna WM, Abdel-Fattah S, el-Rasad MM, Wassef EL. The prevalance of delta virus infection in chronic liver disease in Egyptian children in comparison with some other countries. Panminerva Med. 2000;42(2):97-100.

77. al Adhani MS. Hepatitis B core and surface antigens and delta agent in chronic liver disease in Kuwait. Histol Histopathol. 1988;3(1):57-62.

78. Al-Moslih MI, Al-Huraibi MA. Prevalence of hepatitis C virus among patients with liver disease in the Republic of Yemen. East Mediterr Health J. 2000;6(4):77-8.

79. Arya SC, Ashraf SJ, Parande CM, Tobeiqi MS, Ageel AR. Hepatitis B and delta markers in primary hepatocellular carcinoma patients in the Gizaan area of Saudi Arabia. APMS Suppl. 1988;30-40.

80. Bashardust n. seroprevalence of HDV in high risk group. Med J Shahid Sadoughi. 1993;751.

81. Parci P, Burroughs AK, Thomas HC, Shamma A, Meltzer DJ. Prevalence of delta hepatitis and delta markers in primary hepatocellular carcinoma patients in the Gizaan area of Saudi Arabia. APMS Suppl. 1988;30-40.

82. Bashardust n. seroprevalence of HDV in high risk group. Med J Shahid Sadoughi. 1993;751.

83. Parci P, Burroughs AK, Thomas HC, Shamma A, Meltzer DJ. Prevalence of delta hepatitis and delta markers in primary hepatocellular carcinoma patients in the Gizaan area of Saudi Arabia. APMS Suppl. 1988;30-40.

84. Bashardust n. seroprevalence of HDV in high risk group. Med J Shahid Sadoughi. 1993;751.

85. Parci P, Burroughs AK, Thomas HC, Shamma A, Meltzer DJ. Prevalence of delta hepatitis and delta markers in primary hepatocellular carcinoma patients in the Gizaan area of Saudi Arabia. APMS Suppl. 1988;30-40.

86. Bashardust n. seroprevalence of HDV in high risk group. Med J Shahid Sadoughi. 1993;751.

87. Parci P, Burroughs AK, Thomas HC, Shamma A, Meltzer DJ. Prevalence of delta hepatitis and delta markers in primary hepatocellular carcinoma patients in the Gizaan area of Saudi Arabia. APMS Suppl. 1988;30-40.

88. Bashardust n. seroprevalence of HDV in high risk group. Med J Shahid Sadoughi. 1993;751.
Prevalence of Hepatitis D in EMRO

Amini N et al.

Hepat Mon. 2013;33(1):e8210
Prevalence of Hepatitis D in EMRO

Amini N et al.

141. Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg. 1997;41(1):31-4.

142. el Guneid AM, Gunaid AA, O'Neill AM, Zureikat NI, Coleman JC, Murray-Lyon IM. Prevalence of hepatitis B, C, and D virus markers in Yemeni patients with chronic liver disease. J Med Virol. 1993;40(4):330-3.

143. Scott DA, Burans JP, al-Ouzeib HD, Arunkumar BK, al-Fadeel M, Nigad YR, et al. A seroepidemiological survey of viral hepatitis in the Yemen Arab Republic. Trans R Soc Trop Med Hyg. 1990;84(2):286-9.

144. Al-Arabi MA, Hyams KC, Mahgoub M. Non-A, non-B hepatitis in Omdurman, Sudan. J Med Virol. 1987;21(3):217-22.

145. Woodruff PW, Morrill JC, Burans JP, Hyams KC, Woody JN. A study of viral and rickettsial exposure and causes of fever in Juba, southern Sudan. Trans R Soc Trop Med Hyg. 1988;82(5):761-6.

146. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int. 2011;31(1):7-21.

147. Fonseca JC, Simonetti SRR, Schatzmayr HG, Castejón MJ, Cesário ALO, Simonetti JP. Prevalence of infection with hepatitis delta virus (HDV) among carriers of hepatitis B surface antigen in Amazonas State, Brazil. Trans R Soc Trop Med Hyg. 1988;82(3):469-471.

148. Hadler SC, Alcala de Monzon M, Rivero D, Perez M, Bracho A, Fields H. Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol. 1992;136(2):350-7.

149. Degerkezen H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;28(4):494-8.

150. Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005;77(4):491-9.

151. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46(3):420-6.

152. Saracco G, Rosina F, Brunetto MR, Amoroso P, Caredda F, Farci P, et al. Rapidly progressive HBsAg-positive hepatitis in Italy: The role of hepatitis delta virus infection. J Hepatol. 1987;7(3):274-281.

153. Chang SY, Yang CL, Ko WS, Liu WC, Lin CY, Wu CH, et al. Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan. J Clin Microbiol. 2011;49(3):1083-9.

154. Ewokedilioka SC, Ijeoma U. Seroprevalence of antibody to HDV in Nigerians with hepatitis B virus-related liver diseases. Niger J Clin Pract. 2009;12(4):439-42.

155. Rapicetta M, Hailu K, Ponzetto A, Hele C, Morace G, Bekura D, et al. Delta hepatitis virus infection in ethiopia. Eur J Epidemiol. 1988;4(2):185-188.

156. Foupouapouognigni Y, Noah DN, Sartre MT, Nfoutou R. High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon. J Clin Microbiol. 2011;49(3):1062-4.

157. Kim HS, Kim SJ, Park HW, Shin WG, Kim KH, Lee JH, et al. Prevalence and clinical significance of hepatitis D virus co-infection in patients with chronic hepatitis B in Korea. J Med Virol. 2011;83(7):1172-7.

158. Chakraborty P, Kailash U, Jain A, Goyal R, Gupta RK, Das BC, et al. Seroprevalence of hepatitis D virus in patients with hepatitis B virus-related liver diseases. Indian J Med Res. 2005;122(3):254-7.

159. Chen X, Xuan M, Yin Y. [Study of HDV infection in Shandong province]. Zhonghua Liu Xing Bing Xue Za Zhi. 1998;19(3):338-40.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله